FRONTEO, Inc.

Caion has entered into a joint research agreement with FRONTEO regarding AI drug discovery. Additionally, CAPITA will record a special gain in the second quarter of the fiscal year ending March 2027 due to the sale of idle land. JMHD has revised down its consolidated earnings forecast for the fiscal year ending July 2026. Nexera has received a milestone payment of $86 million from Centessa based on progress in late-stage development. DWTi has decided on a domestic development plan for its glaucoma treatment agent H-1337. Blangista has seen additional share acquisition by SBINM LLC in connection with the strengthening of capital ties with SBI.

FRONTEO announced that it has launched the second co-creation project with Santen utilizing the AI KIBIT. This project aims to discover unknown relationships between diseases and target molecules in a discontinuous manner, with the goal of expanding Santen's pipeline. It follows the co-creation project initiated in December 2025 on novel target molecule exploration and drug repositioning.